Chinese patent medicine for treating senile hemiplegia

It is concluded that element E is a cutting-edge medical research achievement that can significantly reduce cholesterol, triglyceride and low-density lipoprotein, significantly increase high-density lipoprotein, and overcome the world problem of "lipid triad". Tokyo University, Osaka University, American Heart, Lung and Blood Institute, Kansas University, French National Institute of Health and Medicine, Geneva University, Shandong University, Shenyang Pharmaceutical University, Shandong University of Traditional Chinese Medicine, Zhejiang Medical University, Suzhou University, and Shandong Academy of Medical Sciences Institute of New Drugs were developed after more than eight years of international research and clinical experiments. On the basis of high-efficiency regulation of blood lipids, element E can significantly reduce homocysteine and prevent and treat cardiovascular and cerebrovascular diseases caused by factors other than high cholesterol and hypertension. Strongly reverse atherosclerosis, prevent and treat cardiovascular and cerebrovascular diseases such as vascular stenosis caused by vascular smooth muscle cell proliferation. The clinical efficacy has far exceeded the mainstream cardiovascular and cerebrovascular drugs statins and aspirin, which is the first innovation in the treatment of cardiovascular and cerebrovascular diseases with preserved cardiovascular and cerebrovascular functions. Product description Product name: E element English name: E factor capsule effective ingredients and content: total saponins (calculated by artist Shen saponin Re) 280mg, tea polyphenols 2 1400mg, total flavonoids (calculated by rutin) 370mg Invention patent number: 03 1 12485.2 Product implementation standard: Q/. Production unit: Shandong Jinan Johnson Biotechnology Co., Ltd. The efficacy of the product is 1, and the efficacy of E element on blood lipid is 37.8%, 68.8%, 45.4% and 2 1% respectively. Overall, it is better than the control group, which is 26.7%, 27%, 36.5% and -3% of octreotide respectively. The control group has no effect on raising high-density lipoprotein, but it has a downward trend. Even the best data of lowering low-density lipoprotein is far behind E element. This data is also better than the data of Nordic octreotide (4s) survival study: 4,444 patients were clinically observed for 4 years. In octreotide group, the total cholesterol, low-density lipoprotein and triglyceride decreased by 25%, 35% and 10% respectively, while high-density lipoprotein increased by 8%. "2. The effect of vitamin E on cholesterol. E can significantly reduce the levels of VLDL, LDL and intermediate density lipoprotein (IDL) in plasma, as well as the levels of cholesterol in liver and aorta, with the maximum reductions of 70%, 80%, 25% and 25% respectively. The activity of LDL receptor and the expression of protein in liver increased significantly. By reducing cholesterol synthesis and up-regulating LDL receptor in liver, cholesterol levels in plasma, liver and aorta can be reduced. 3. The role of element E in cardiovascular and cerebrovascular pathogenic factors. The effective rate of reducing serum total cholesterol by element E was 96.6%, and the cure rate was 66.7%. The effective rate of reducing triglyceride 100%, the cure rate 80%, the effective rate of increasing high density lipoprotein 96.6%, and the cure rate 76.6%. The effective rate of reducing low density lipoprotein is 93.3%, and the cure rate is as high as 60%. The effective rate of treating fatty liver is 94.65438 0%, that of treating obesity is 965438 0.3%, and that of reducing hypertension is 96.6%. The effective rates for arteriosclerosis and coronary heart disease were 965,438 0.6% and 85.7%, respectively, among which 37.5% and 38.65,438 0% were remarkable. The effective rate of sequelae of cerebral thrombosis is 100%, and the prognosis of 60% is remarkable. Thrombosis of platelets decreased by 34% and venous thrombosis decreased by 68%. The effective rate of habitual constipation is 100%, of which 90% has obvious curative effect; Eliminate the risk of inducing cardiovascular and cerebrovascular bleeding. 4. Comparison of the Use of E and Aspirin "Clinical Report on the Effects of E and Aspirin on Prostacyclin and Thromboxane in Patients with Hypertension and Coronary Heart Disease" shows that the plasma thromboxane B2 level in the two groups decreased before and after treatment, and the ratio of 6- keto-prostaglandin F 10/ thromboxane B2 increased, which has the same effect; After two weeks of continuous treatment, the E element treatment group found that it can further reduce the plasma thromboxane B2 level, especially in patients with old myocardial infarction, and significantly inhibit platelet aggregation, suggesting that longer-term treatment may be more meaningful. Conclusion: After 2 weeks of treatment, the effect of E element is similar to that of aspirin in reducing thromboxane B2 and increasing the ratio of 6- keto-prostaglandin F 10/ thromboxane B2. In view of the fact that even a small dose of aspirin can not avoid the risk of severe bleeding complications, element E is safer and has a broader application prospect. 5. The effect of E on platelets, the effect of E on platelet aggregation and activation, and the production of TXB2, P-SE- selectin and platelet membrane glycoprotein P- selectin in human platelet-rich plasma provide a basis for further development of antiplatelet drugs. Results: E can obviously inhibit platelet aggregation (P